【Post-Event Report】Forum on Legal Trends in the Commercial Use of Health Data (Opening Speeches)

Director Lee Po-chang of the Health and Welfare Policy Research Center expressed that the theme of this forum is “Exploring Legal Trends in the Commercial Use of Health Data.” It focuses on the legal aspects of the commercial use of health data. He pointed out that striking a balance between using health data and protecting patient privacy is a critically important issue. In this data-driven era, health data has become a crucial element in the fields of healthcare, research, and business. However, the use of this data must be accompanied by strict legal and ethical regulations to ensure patient privacy and data security. He encouraged participants to actively engage in discussions and share their insights.

Mr. Lee Ke-wen, Legal Counsel of Taiwan Nova Corporation, stated that health data plays a vital role in medical science and business innovation. He mentioned that de-identified health data in large quantities holds a pivotal position in drug research, efficacy assessment, and precision medicine. Regulations should provide more incentives and flexibility to facilitate the legal use of health data. He emphasized the challenging balance between safeguarding patient privacy and enabling data-driven innovation. Taiwan Nova Corporation is eager to collaborate with Taipei Medical University and contribute to discussions on legal trends in health data.

Mr. Salah Mostafa, Legal Counsel for the Asia-Pacific, Middle East, and Africa regions of Nova, expressed that Taiwan’s national health insurance system and medical market prospects have attracted Nova’s attention, making it an ideal investment choice. He pointed out that health data is a key element for personalized treatment and drug development. He expressed confidence in Taiwan’s active development and looked forward to collaborative efforts in this age of big data to find ways to balance patient privacy rights and promote advancements in medical science and business innovation.

Mr. Chen Chuan-wen, Secretary-General of the Developmental Pharmaceutical Research Association of the Republic of China, stated that the application of medical big data is a worthwhile investment area that can enhance the level of personalized disease prevention and treatment, ushering in a new era for the people of Taiwan. He shared the importance of medical big data in drug development and called for legal frameworks to evolve in order to promote further applications of health data.